Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24558306 | 0.81 | — | — | |
| SCHEMBL29693174 | 0.81 | ALDH1A1 (0.40) | TARBP2CYP1A2ALDH1A1PTPN2ELANE | |
| SCHEMBL31107210 | 0.81 | ALDH1A1 (0.40) | TARBP2CYP1A2ALDH1A1PTPN2ELANE | |
| SCHEMBL31107271 | 0.78 | TARBP2 (0.41) | TARBP2CYP1A2ALDH1A1TSHRGLP1R | |
| SCHEMBL17362538 | 0.68 | TARBP2 (0.42) | TARBP2ALDH1A1ELANETSHRKDM4E | |
| SCHEMBL20301674 | 0.68 | CFTR (0.44) | TARBP2CYP1A2ALDH1A1PTPN2TSHR | |
| SCHEMBL1819905 | 0.67 | TSHR (0.48) | ALDH1A1TSHRKDM4EKMT2AL3MBTL1 | |
| SCHEMBL30200423 | 0.66 | TARBP2 (0.46) | TARBP2CYP1A2ALDH1A1TSHRPDE4A | |
| SCHEMBL25260946 | 0.65 | TSHR (0.47) | ALDH1A1TSHRKDM4EMAPK1KMT2A | |
| SCHEMBL1795334 | 0.65 | TARBP2 (0.44) | TARBP2CYP1A2ALDH1A1GLP1RKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | TARBP2 1066/4885CYP1A2 464/4885ALDH1A1 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.